Raphael Labs is led by a strong management team with a diverse background and deep experience in the biopharmaceutical industry and academia.
Prof. Rakesh Uppal Consultant Cardiac Surgeon at Barts Heart Centre and Professor of Cardiovascular Surgery at QMUL. He is the Director of Barts Life Sciences, a collaboration between academia, clinicians and industry to transform patient care. He is currently working on stem cell therapy for the failing heart and understanding the genetic basis of cell senescence in acute renal injury following cardiac interventions.
Prof. Steve Davies* Waynflete Professor Emeritus of Chemistry at Oxford University, founded and invested in several companies, including Oxford Asymmetry Ltd and Oxford Diversity Ltd (combined and sold to Evotec in 2000 at a valuation of £316m), NASDAQ listed Summit Therapeutics Inc and Oxstem Ltd where he heads a multidisciplinary research team in regenerative medicine at Oxford.
Prof. Angela Russell Professor of Medicinal Chemistry at the University of Oxford. She has founded two companies MuOx Ltd (acquired by Summit Therapeutics plc) and Oxstem Ltd to translate her research towards new treatments. She currently leads a multidisciplinary research team developing new therapies for degenerative diseases at Oxford.
Professor Áine McKnight Professor of Viral Pathology at the Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London. Professor McKnight has dedicated her career to HIV/AIDS research. Her current research group is focused on novel host cell restriction factors that inhibit HIV replication. During the Covid-19 pandemic she has repurposed her skills to investigate the immune responses to SARS-CoV-2 in natural infection and after vaccination.
Prof. Dame Kay Davies, CBE FMedSci, Dr Lee’s Professor of Anatomy at the University of Oxford and Co-Director of the MDUK Oxford Neuromuscular Centre. She has co-founded companies to translate her work to the clinic. She was Deputy Chair of Wellcome (2013-17), chairs the Genomics England Clinical Interpretation Partnership and is a member of the GRL Board at the Sanger Institute.
Dr. Laurence Silpa Doctorate in Medicinal Chemistry, University of Tours and the Institut National de Recherche Agronomique. Joined Professor Angela Russell’s team 2015. Post-doctoral positions in collaboration with StemBANCC’s consortium, an academic- industry partnership in the area of stem cell research and Oxstem Ltd, a regenerative medicine drug discovery company.
Enda O’Connell* Experienced Chartered Accountant with over 10 years’ experience managing businesses across a number of jurisdictions with overall asset values of €100m +.
John Mara* Investor with significant hands-on experience in acquiring and building profitable start-up businesses internationally. Expertise across TMT, FinTech, manufacturing and aerospace/defence.
Donal Boylan Former Vice Chair of Bohai Capital Holdings, China’s largest equipment lessor. CEO of CDB Aviation Lease Finance ($25bn publically listed CDB Leasing). Head of aerospace and defence structured asset finance at RBS Aviation Capital. Co-founder and partner of BCAP.
Nicola Burdett Communications and strategy consultant. Former BBC journalist and news producer. Served as a Special Advisor to the UK Prime Minister at 10 Downing Street between 2008-10. Advisory board member of One Million Mentors.
Tony Powell Chief Technical Officer. Entrepreneurial technologist who has experience with numerous tech start-ups, agencies and global brands over the last 20 years.
Dr. Jim Swales Physician with regulatory experience at the MHRA and wide medical and clinical development experience in the pharmaceutical industry. Currently working as an independent consultant to the pharmaceutical industry on regulatory, medical and clinical matters.
David Wheeler 30 years of Senior Executive Management, Directorships, and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients, and ASX listed companies. David has experience on public and private company boards and currently holds several Directorships and Advisory positions in Australian companies. David is a Fellow of the Australian Institute of Company Directors.
Jason Peterson* Managing Director of CPS Capital with Series 7 USA and SDIA/Finsia qualifications. CPS is the largest investment house in Australia per deal frequency in class. Specialises in company advising, investing, restructuring and listing: trading across six sectors including biotech, mining and TMT.
Fabio Pannuti* Founding Shareholder Raphael Labs Managed wealth for two ultra-high net worth families over the last decade. Recently the Chief Executive Officer of the Lauder Family Office managing a portfolio of over $9bn across several asset classes (fund management, venture capital, private equity, listed equities). Senior executive of the advisory board for the $3bn Semper fund, which remains GP controlled by the Lauder and Parsons families.
* Founding Shareholder Raphael Labs